% | $
Quotes you view appear here for quick access.

Endocyte, Inc. Message Board

  • chirag_487a chirag_487a Mar 24, 2014 2:04 PM Flag

    Red Acre writes before AF can strike

    TARGET Lung Cancer trial succeeds

    On Friday ECYT also reported that the phase 2 TARGET trial on vintafolide in FR100% non-small cell lung cancer patients met its primary endpoint. The combination of vintafoldie plus docetaxel showed a progression free survival hazard ratio of 0.75 with a p-value of 0.0696 using a 1-sided test.

    Note, a p-value 0.0696 is greater than 0.05 - so how does ECYT consider this a success? The pre-specified significance criteria according to the trial's statistical analysis plan was p

3.13-0.08(-2.49%)Jul 25 4:00 PMEDT